Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type! y0 o! p5 I4 F, d5 R4 ]) y
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
{8 B9 p! S% H9 I+ k" z' T+ Author Affiliations% B; D+ j9 s, h7 s2 d
0 Y9 ^$ j# i( @; I! r6 `/ Y3 |1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
3 N. T8 E8 F0 V1 j3 @2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 ^% Z; }3 ^2 f. ?$ K, T
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
) X0 o, X! m9 {: Q4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
( N E e9 Q C* v5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ) z% P/ |- k& l( u( r3 i
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
- |9 G7 g% i/ i7Kinki University School of Medicine, Osaka 589-8511, Japan - t- |9 c3 _' D/ S* H( j" B" [
8Izumi Municipal Hospital, Osaka 594-0071, Japan
7 b3 v3 Y. j5 \+ ~9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
- E* ]1 X6 a+ K, D! `2 g5 D3 M$ GCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
$ o& s3 s) ]8 G3 t* M9 o0 [! VAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 1 i6 n& C6 W+ P6 m6 l
3 |6 P+ O! i0 A+ F( v4 x |